Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

At 8.25% CAGR, Oncology Information System Market Size, Share is Expected to Reach US$ 2.25 billion in 2029

Published

on

<!– Name:DistributionId Value:8780411 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1244655 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:10d3500d-729c-4bde-9f73-dfae19efb7d1 –>

Luton, Bedfordshire, United Kingdom, March 02, 2023 (GLOBE NEWSWIRE) — Exactitude Consultancy, the market research and consulting wing of Ameliorate Digital Consultancy Private Limited has completed and published the final copy of the detailed research report on the Oncology Information System market.

Global Oncology Information System Market stands at US$ 7.59 Billion in 2022 and is anticipated to grow at a CAGR of 8.25% over the following Six years to reach US$ 13.44 billion by 2029.

Oncology information systems for various medical devices are extremely expensive. Affordability is a big issue for healthcare businesses, particularly in emerging economies, where budgetary clearances for IT solutions over medical equipment are often difficult to come by. Smaller healthcare organizations struggle to connect medical devices to the Internet, owing to challenges such as integrating various networks with health setups, a lack of wireless connectivity alternatives, and the requirement to add security layers to prevent data breaches.

Oncology information systems (OIS) are software programs that manage a huge amount of clinical and non-clinical data for cancer patients. This system facilitates data integration in a variety of phases, including screening, prevention, diagnosis, and therapy. In the forecasted timeframe, factors such as increasing usage of OIS solutions and rising cancer cases are predicted to have a significant impact. According to the National Cancer Institute, by 2040, the number of new cancer cases will increase by 29.5 million, while cancer-related fatalities will rise to 16.4 million every year.

Click & Get a Free Sample Report in Minutes: https://exactitudeconsultancy.com/reports/10178/oncology-information-system-market/#request-a-sample       

Oncology Information System Market Growth Insights

Rising incidence of cancer: The demand for oncology information systems is being driven by the quickly rising incidence of cancer worldwide. In order to effectively handle cancer patients, healthcare providers need to be able to manage patient data, monitor treatments, and measure outcomes.

Increasing adoption of electronic health records: The market for oncology information systems is expanding as a result of the fast uptake of electronic health records (EHRs). To give healthcare professionals a comprehensive picture of patient health data, which is essential for the efficient management of cancer patients, oncology information systems can be integrated with EHRs.

Technological advancements: Innovation in the market for oncology information systems is being driven by technological developments like artificial intelligence, machine learning, and big data analytics. These technologies can assist medical professionals in personalizing treatment plans, increasing the precision of cancer diagnoses, and keeping track of patient outcomes.

Increasing demand for personalized medicine: Oncology information systems are being adopted due to the rising demand for personalized medicine in the therapy of cancer. In order to improve therapy outcomes, these systems can assist healthcare professionals in creating individualized treatment plans based on patient-specific data.

Competitive Insight

Some of the notable market players operating in the global Oncology Information System Market covered in this report are:

  • Varian Medical Systems Inc
  • McKesson Corporation
  • Siemens Healthineers
  • Elekta AB
  • Epic Systems Corporation
  • IBM
  • Cerner Corporation
  • Advanced-Data Systems
  • Bogardus Medical Systems, Inc

Recent Developments

  • In January 2022, Elekta announced the launch of Elekta Unity, a new imaging system that combines magnetic resonance imaging (MRI) with linear accelerator (linac) technology for improved cancer treatment planning.
  • In December 2021, Cerner Corporation announced a partnership with Genomic Health, Inc. to integrate genomic data into Cerner’s electronic health record (EHR) platform for more personalized cancer treatment planning.
  • In November 2021, Philips Healthcare announced the launch of its new IntelliSpace Radiation Oncology platform, which offers integrated oncology software solutions to support clinical decision-making in radiation therapy.
  • In October 2021, Varian Medical Systems announced the launch of its new Eclipse v16.1 treatment planning software, which incorporates artificial intelligence and machine learning capabilities for more accurate and personalized cancer treatment planning.
Attributes Value
Oncology Information System Market Share (2022) US$ 7.59 Billion
Oncology Information System market Projected Size (2029) US$ 13.44 billion
Oncology Information System Market Growth (CAGR 2023-2029) 8.25%.

Browse the fullOncology Information System Market by Software (Patient Information System, TPS, RIS, PACS, Services), Application (Medical, Radiation, Surgical Oncology), End-user (Hospitals, Cancer Care Centers, Government Institution, Academia), and Region (Asia-pacific, North America, Europe, South America, Middle East & Africa) – Global Forecast from 2023 to 2029Report and TOC at https://exactitudeconsultancy.com/reports/10178/oncology-information-system-market/

Segment Overview

The Oncology Information System Market is segmented by Software, By end user, and by Application.

Understanding the Oncology Information System market requires segmentation because it enables businesses to create goods and services that are specifically catered to the requirements of their target market. For instance, treatment management systems may be better suited for oncology offices while treatment planning systems may be better suited for hospitals and research facilities. Similarly to this, smaller healthcare facilities might benefit more from cloud-based deployment, whereas larger hospitals might favor on-premise deployment. In general, segmentation aids businesses in locating the most promising market prospects and creating efficient customer-targeting strategies.

By Software  By Application By end user
  • Patient information system
  • TPS
  • RIS
  • PACS
  • Services
  • Medical
  • Radiation
  • Surgical oncology

 

  • Hospitals
  • Cancer care centers
  • Government institution
  • Academia

To learn more about this report, request a free sample copy

 Oncology Information System Market Regional Insights

North America: The United States is the main driver of market development in North America, which is home to the largest market for oncology information systems. The market is fueled by the existence of numerous hospitals and study institutes, government programs to enhance cancer care, and the rising adoption of cutting-edge technologies.

Asia-Pacific: The market for oncology information systems is predicted to expand at the highest rate in the Asia-Pacific region due to rising government spending on healthcare, an increase in cancer incidence, and a growing uptake of cutting-edge technologies.

Quantitative Analysis

  • Market size, estimates, and forecasts from 2023 – 2029
  • Market size and revenue estimates for products up to 2029
  • Market revenue estimates for application up to 2029
  • Market revenue estimates for type up to 2029
  • Regional market size and forecast up to 2029
  • Company financial

What are the Key Data Covered in this Oncology Information System Market Report?

  • CAGR of the market during the forecast period 2023-2029
  • Detailed information on factors that will drive Oncology Information System Market growth during the next Six years
  • Precise estimation of the Oncology Information System Market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the Oncology Information System industry across North America, Europe, APAC, South America, the Middle East, and Africa
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of Oncology Information System Market vendors

To know an additional revised 2023 list of market players, request a sample report: https://exactitudeconsultancy.com/reports/10178/oncology-information-system-market/#request-a-sample       

Browse Other Related Research Reports from Exactitude Consultancy

Esoteric Testing Market is expected to reach above USD 50.17 billion by 2029.

Medical Image Analysis Software Market is expected to reach above 6.45 USD billion by 2029.

Diagnostic Imaging Market is expected to grow till USD 43.74 Billion by 2029.

Interventional Oncology Market is expected to reach above USD 3.35 billion by 2029


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Brainomix Achieves Breakthrough with FDA Clearance of e-Lung AI Software

Published

on

brainomix-achieves-breakthrough-with-fda-clearance-of-e-lung-ai-software

Established market leader in stroke AI imaging receives its first FDA clearance in the lung imaging space.With this expanded foundation of AI-driven healthcare solutions, the Oxford-based company remains committed to driving innovation and delivering impactful advancements in imaging biomarkers.OXFORD, England, and CHICAGO, May 17, 2024 /PRNewswire/ — Brainomix, a pioneer in artificial intelligence (AI) imaging solutions to enable precision medicine, is proud to announce the FDA clearance of its latest product, Brainomix 360 e-Lung. Brainomix’s entry into the lung imaging space follows a series of successful clearances and widespread clinical adoption of its Brainomix 360 Stroke platform in both the US and Europe.

The clearance of e-Lung marks a significant milestone in Brainomix’s journey to expand its footprint in medical imaging beyond stroke-related applications and represents a notable step forward in the quest for advanced lung imaging solutions. The company, with its rich academic heritage and record of scientific excellence, will expand its research collaborations in the pulmonology space to yield new insights to inform future iterations of e-Lung and chart a path towards continual improvements for the lung imaging technology.
Dr Deji Adegunsoye, Assistant Professor of Medicine and Scientific Director of the Interstitial Lung Disease Program at University of Chicago Medicine, said: “This is an exciting step for Brainomix, who have a demonstrated track record of developing novel AI-based solutions in stroke and are now applying that expertise to develop innovative tools in the lung space. The preliminary data for e-Lung is impressive and would indicate that we have a promising tool that could help to expedite healthcare delivery and improve clinically meaningful outcomes for patients with lung disease.”
Brainomix recently announced the publication of a new study1 in the prestigious peer-reviewed journal American Journal of Respiratory and Critical Care Medicine (AJRCCM), resulting from a research collaboration with AstraZeneca. The results showed that Brainomix’s proprietary lung imaging biomarkers, which include the weighted reticulovascular score (WRVS), stratified patients at risk of Idiopathic Pulmonary Fibrosis (IPF) progression, outperforming standard measures.
Dr Michalis Papadakis, CEO and Co-Founder of Brainomix, said: “We are harnessing our expertise in AI-powered imaging to develop novel biomarkers in other disease indications where AI can support imaging-based diagnostic and treatment decisions.
“This e-Lung FDA clearance reflects our focus on developing innovative solutions that empower healthcare professionals with cutting-edge tools for sophisticated disease evaluation, enhancing access to treatments that can ultimately work to improve patient outcomes.”
Brainomix will be presenting its latest e-Lung data at the American Thoracic Society (ATS) annual conference in San Diego May 17th – 22nd, including results from research collaborations with Heidelberg University and with Seattle-based Avalyn Pharma.
Am. J. Respir. Crit. Care Med.: 2024 Feb 16 – e-Lung CT Biomarker Stratifies Patients at Risk of IPF Progression in a 52-Week Clinical Trialhttps://www.atsjournals.org/doi/abs/10.1164/rccm.202312-2274LEAbout Brainomix
Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke and lung fibrosis. With origins as a spin-out from the University of Oxford, Brainomix is an expanding commercial-stage company with offices in the UK, Ireland and the USA, and operations in more than 30 countries. A private company, backed by leading healthtech investors, Brainomix has innovated award-winning imaging biomarkers and software solutions that have been clinically adopted in hundreds of hospitals worldwide. Its first product, the Brainomix 360 stroke platform, provides clinicians with the most comprehensive stroke imaging solution, driving increased treatment rates and improving functional independence for patients.
To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on Twitter, LinkedIn and Facebook.
Contacts
Jeff Wyrtzen, Chief Marketing & Business Development [email protected] +44 (0)7927 164210T +44 (0)1865 582730
Media enquiries
Charles ConsultantsSue [email protected] M +44 (0)7968 726585
Logo – https://mma.prnewswire.com/media/1989193/3856380/Brainomix_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/brainomix-achieves-breakthrough-with-fda-clearance-of-e-lung-ai-software-302144836.html

Continue Reading

Artificial Intelligence

CUBE acquires global regulatory intelligence businesses from Thomson Reuters

Published

on

cube-acquires-global-regulatory-intelligence-businesses-from-thomson-reuters

LONDON, May 17, 2024 /PRNewswire/ — CUBE, a global leader in Automated Regulatory Intelligence (ARI) and Regulatory Change Management (RCM), announces today its acquisition of the Thomson Reuters Regulatory Intelligence and Oden products and businesses.

The acquisition of these global businesses represents a major step forward in CUBE’s growth plans. It will deliver significant scale across many of the world’s leading and systemically important financial institutions. CUBE’s existing global customer base will be expanded to total approximately 1,000 customers in banking, insurance, asset and investment management, payments and adjacent regulated industries.
CUBE’s global employees will expand to 600, of which close to 250 are highly qualified regulatory subject matter experts, legal and compliance professionals.
Ben Richmond, founder and CEO of CUBE said: “Thomson Reuters is known to be the biggest and best in the industry for providing regulatory expert analysis and subject matter expertise, alongside world-leading journalism and news. The combination of CUBE’s purpose-built AI, with the years of content curated by Thomson Reuters Regulatory Intelligence and Oden expert analysts, will accelerate innovation. Together, we will deliver regulatory transformation capabilities for our global customers that could only have been imagined before.”
Richmond continues: “This combination will provide tremendous scale and depth across CUBE’s regulatory content and technology. It is a significant step toward creating an industry-defining regulatory compliance and risk platform that will benefit all customers and elevate the industry as a whole.”
Through this acquisition, CUBE will provide an expanded and comprehensive selection of specialized regulatory intelligence and regulatory change services, committed to excellence, quality, and highly contextualised and meaningful regulatory content for customers. By combining cutting-edge technology and subject matter expertise at scale CUBE will set a new bar for the industry in regulatory automation and content.
Chris Maguire, General Manager, Risk and Fraud, Corporates, Thomson Reuters said: “It was clear to us that CUBE had established itself as a leading regulatory intelligence provider for global enterprise clients in the financial services and insurance sectors. We wanted to ensure our customers and employees could work with an organisation that would continue to innovate and significantly invest in solutions like Thomson Reuters Regulatory Intelligence and Oden. We are working tirelessly to ensure a seamless and value-enhancing transition for customers and employees, and we are looking forward to working with the CUBE team during this transition.” 
Christopher Fielding, Hg, said: “We’re delighted to further extend our market reach, bringing in two high quality and complementary global businesses to the CUBE platform.”
Thomas Martin, Hg, added: “We see these acquisitions as enabling further innovation in the regulatory intelligence and change management sector, leading to strengthened demand for these quality solutions across the globe.”
The terms of the transaction will not be disclosed.
About CUBE
CUBE provides a highly comprehensive and robust source of classified, and meaningful AI-driven regulatory data to power its Automated Regulatory Intelligence (ARI) and Regulatory Change Management (RCM) solutions. CUBE’s purpose-built regulatory technology including its AI engine (RegBrain) and software platform (RegPlatform) tracks, analyses, and monitors laws, rules, and regulations in every country and in every published language to create an always up-to-date regulatory footprint that transforms visibility and compliance capability for customers across the globe.
With operations across Europe, North America, Canada, Asia, and Australia, CUBE serves a diverse and global base of customers and partners including the largest financial institutions in the world who leverage CUBE’s platform to streamline their complex regulatory intelligence and change management processes.
Following the strategic partnership with Hg in March 2024, CUBE announced the acquisition of US-based Reg-Room in May 2024.
About Hg
Hg supports the building of sector-leading enterprises that supply businesses with critical software applications or workflow services, delivering a more automated workplace for their customers.
This industry is characterised by digitisation trends that are in early stages of adoption and are set to transform the workplace for professionals over decades to come. Hg’s support combines deep end-market knowledge with world class operational resources, together providing compelling support to entrepreneurial leaders looking to scale their business – businesses that are well invested, enduring and serve their customers well.
With a vast European network and strong presence across North America, Hg’s 400 employees and around $70 billion in funds under management support a portfolio of around 50 businesses, worth over $140 billion aggregate enterprise value, with over 110,000 employees, consistently growing revenues at more than 20%.
About Regulatory Intelligence
Regulatory Intelligence is a proactive, connected, and comprehensive solution that tracks and analyses regulatory changes within ~2,000 regulatory bodies and rulebooks for more than 20 countries. It enables banking, financial services, and insurance (BFSI) sectors to manage exposure to operational, regulatory, and compliance risk.
About Oden
Oden State Rules and Regulations (SR&R), Oden Policy Terminator/Sentry PT, and OdenTrack provide repositories and automated solutions for complying with state rules and regulations on the provisioning of Personal and Business Insurance in the US.

View original content:https://www.prnewswire.co.uk/news-releases/cube-acquires-global-regulatory-intelligence-businesses-from-thomson-reuters-302147604.html

Continue Reading

Artificial Intelligence

Cayman Enterprise City Publishes Socio-Economic Impact Assessment by Economist and Leading Advisor on the Caribbean, Marla Dukharan

Published

on

cayman-enterprise-city-publishes-socio-economic-impact-assessment-by-economist-and-leading-advisor-on-the-caribbean,-marla-dukharan

The Impact of Cayman Enterprise City’s Socio-Economic Development Project Nears USD $1 Billion
GRAND CAYMAN, Cayman Islands, May 16, 2024 /PRNewswire/ — Cayman Enterprise City (CEC) has released a Socio-Economic Impact Assessment by Marla Dukharan. The report illustrates that CEC is increasing its impact by supporting higher earnings for Caymanians and is driving a shift towards a knowledge-based economy by focusing on high productivity sectors. The release by Dukharan reads, “Caymanian resourcefulness and private sector-led innovation have been the driving force behind the islands’ outstanding socio-economic success. Cayman Enterprise City underpins the next generation of Cayman innovation and dynamism.”

With an economic impact of USD $130 million in 2023, contributing just under USD $1 billion to the local economic activity in 12 years since inception, “CEC is helping the nation to diversify economically, in terms of sectors and jobs, ensuring locals have economic and employment opportunities that match the nation’s progress,” the report reads.
The CEC socio-economic development project is now home to 352 Special Economic Zones Companies (SEZCos), many of which are globally recognised institutions led by top executives and industry experts. “CEC member companies are providing high-value employment with salaries exceeding those typically found outside of the special economic zone,” said Charlie Kirkconnell, Chief Executive Officer at CEC. “The CEC community is fully invested in Cayman and the report illustrates that the CEC socio-economic development project is making a very significant impact on Cayman’s economy and community.”
“As CEC continues to grow, it continues to create significant employment and entrepreneurial opportunities for Caymanians and we encourage anyone that might be interested in finding out how they might get involved, whether as a member of the community and/or as a volunteer in our Enterprise Cayman non-profit organisation (NPO).”
77% of Caymanian-held jobs at CEC member companies, are in sectors with high social returns and increasing global demand. “By putting skills first and prioritizing learning, CEC is enabling new industries to take root,” the release by Dukharan reads.
CEC, through its Enterprise Cayman NPO, is a first-mover in private sector-facilitated education and training in the Caribbean, making it a leading force to boost youth participation in the economy. By offering training in specialised skills, Enterprise Cayman is helping to close the gap in higher education and earnings for Caymanians. “Through Enterprise Cayman we’ve set out to strategically support meaningful employment and entrepreneurial opportunities for Caymanians, by providing internship and mentorship opportunities, by hosting skill-building and career focused training, and by providing invaluable networking and community engagement opportunities,” said Kirkconnell.
In 2023 individuals took advantage of 4,226 opportunities to participate in education, training, and career development events and, since launching entrepreneurial programming in 2021, Enterprise Cayman has worked with 41 new Cayman-born business ventures. “We’re helping to develop a local talent pool that meets the demand of Cayman’s growing digital innovation and technology sectors while, in parallel, offering exciting opportunities for individuals to launch new business ventures within an innovative business environment,” said Kirkconnell.  
With CEC’s new campus and state-of-the-art facilities, Signal House, the project “holds the promise of deep, continued economic impact,” the report concludes.
To access CEC’s economic impact assessments and Enterprise Cayman’s annual reports please visit https://www.enterprisecayman.ky/reports. For more information on how to get involved and for upcoming programmes and events visit www.enterprisecayman.ky. 
Website: www.caymanenterprisecity.com LinkedIn: @CaymanEnterpriseCityTwitter:  @CEC_CaymanInstagram: @CaymanEnterpriseCityFacebook: @CaymanEnterpriseCityYouTube: @ceccayman
About Cayman Enterprise City 
Cayman Enterprise City (CEC) is an award-winning development project which consists of three special economic zones (SEZs) focused on attracting knowledge-based and specialised-services businesses to set up a genuine physical presence in the Cayman Islands. The zones included within CEC are Cayman Tech City, Cayman Commodities & Derivatives Centre, and Cayman Maritime & Aviation City. With a dedicated Government Authority, licensing fee concessions and guaranteed fast-track processes, CEC enables international companies to quickly and efficiently establish a Cayman Islands office, which in turn enables them to generate active business income within a tax neutral environment.
About Enterprise Cayman 
Enterprise Cayman is a non-profit organisation (NPO) powered by Cayman Enterprise City in partnership with Cayman Islands’ special economic zone companies (SEZCos). The organisation, which applies the Theory of Change (TOC) methodology, provides Caymanians and residents with access to high-quality learning experiences and opportunities to develop and launch new business ventures, to pursue careers within the technology and innovation sectors, and to join a dynamic network of industry professionals. Let’s grow the next generation of Caymanian innovators and entrepreneurs with Enterprise Cayman!
Logo: https://mma.prnewswire.com/media/1317764/2860789/Cayman_Enterprise_City_Logo.jpg
FOR MORE INFORMATION:Contact: Kaitlyn Elphinstone  Email: [email protected]  

View original content:https://www.prnewswire.co.uk/news-releases/cayman-enterprise-city-publishes-socio-economic-impact-assessment-by-economist-and-leading-advisor-on-the-caribbean-marla-dukharan-302148206.html

Continue Reading

Trending